Yaohe Wang

Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.

Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal.

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.

Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.

Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice.

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.

Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin.

Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy.

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells.

Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.

Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.

Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes.

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

PRSS3 promotes tumour growth and metastasis of human pancreatic cancer.

Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer.

Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.

Systemic delivery of oncolytic viruses: hopes and hurdles.

A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.

Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway.

Update on oncolytic viral therapy - targeting angiogenesis.

STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirus.

A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer.

Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system.

A novel compound WISP3 mutation in a Chinese family with progressive pseudorheumatoid dysplasia.

Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer.

A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9.

Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.

CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses.

The efficacy of oncolytic adenovirus is mediated by T cell responses against virus and tumor in Syrian hamster model.

Haploinsufficiency of Hand1 improves mice survival after acute myocardial infarction through preventing cardiac rupture.

Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment.

Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer.

Correction for Spurrell et al., "STAT1 Interaction with E3-14.7K in Monocytes Affects the Efficacy of Oncolytic Adenovirus".

Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.